Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132234) titled 'The efficacy of telitacicept in the treatment of generalized myasthenia gravis and its immune-serological response characteristics: A prospective, multicenter real-world study' on Sept. 10.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The Affiliated Hospital of Xuzhou Medical University
Condition:
Myasthenia Gravis
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-15
Target Sample Size: Telitacicept treatment group (Telitacicept 240 mg was administered subcutaneously once a week for 24 consecutive weeks):60;
Countries of Recruitment:
Chin...